<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03315793</url>
  </required_header>
  <id_info>
    <org_study_id>14937</org_study_id>
    <secondary_id>F1J-JE-B058</secondary_id>
    <secondary_id>1701A3631</secondary_id>
    <nct_id>NCT03315793</nct_id>
  </id_info>
  <brief_title>A Study of Duloxetine (LY248686) in Japanese Children and Adolescents With Depressive Disorder</brief_title>
  <official_title>A Double-blind, Efficacy and Safety Study of Duloxetine Hydrochloride Versus Placebo in the Treatment of Japanese Children and Adolescents With Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shionogi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shionogi Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of duloxetine hydrochloride versus
      placebo in the treatment of Japanese children and adolescents with depressive disorder.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 4, 2017</start_date>
  <completion_date type="Actual">November 8, 2019</completion_date>
  <primary_completion_date type="Actual">November 8, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change from Baseline on the Children's Depression Rating Scale-Revised (CDRS-R) Total Score</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Mean change from baseline on the CDRS-R total score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Whose CDRS-R Total Score Decreased by More than 30% from Baseline</measure>
    <time_frame>Week 6</time_frame>
    <description>Percentage of participants whose CDRS-R total score decreased by more than 30% from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Whose CDRS-R Total Score Decreased by More than 50% from Baseline</measure>
    <time_frame>Week 6</time_frame>
    <description>Percentage of participants whose CDRS-R total score decreased by more than 50% from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Total CDRS-R Score ≤ 28</measure>
    <time_frame>Week 6</time_frame>
    <description>Percentage of participants with total CDRS-R score ≤ 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline on Clinical Global Impression-Severity (CGI-S)</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Mean change from baseline on CGI-S</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">149</enrollment>
  <condition>Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Duloxetine Hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duloxetine hydrochloride given orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine Hydrochloride</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Duloxetine Hydrochloride</arm_group_label>
    <other_name>LY248686</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants diagnosed with Major Depressive Disorder or persistent depressive
             disorder and completely meet the criteria of major depressive episode as defined by
             the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) with
             the Mini International Neuropsychiatric Interview for Children and Adolescents
             (MINI-KID) ver.7.0.2.

          -  Participants whose incipient age of depression was ≥7 years old.

          -  Total score of CDRS-R is ≥40 and CGI-S score is ≥4 at both screening and baseline.

        Exclusion Criteria:

          -  Have remarkable response to psycho-education (defined as &gt;30% decrease in the total
             score of CDRS-R between screening and baseline).

          -  Have a current or previous diagnosis (DSM-5) of the following as judged by the
             investigator:

               -  Neurodevelopmental disorders

               -  Schizophrenia spectrum and other psychotic disorders

               -  Bipolar and related disorders

               -  Trauma and stressor-related disorders

               -  Disruptive · Impulse Control · and Conduct disorders

          -  Have a current diagnosis (DSM-5) of the following as judged by the investigator:

               -  Obsessive-compulsive and related disorders

               -  Anorexia nervosa, Bulimia nervosa, Binge-eating disorder

               -  Sleep-wake disorders

               -  Neurocognitive disorders

               -  Disruptive mood dysregulation disorder

          -  Have personality disorders, in the judgement of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shionogi Clinical Trial Administrator Clinical Support Help Line</last_name>
    <role>Study Director</role>
    <affiliation>Shionogi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shionogi</name>
      <address>
        <city>Osaka</city>
        <zip>541-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 1, 2020</verification_date>
  <study_first_submitted>October 17, 2017</study_first_submitted>
  <study_first_submitted_qc>October 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2017</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

